A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected Patients
- Conditions
- HIV Infections
- Registration Number
- NCT00002435
- Lead Sponsor
- Pharmacia
- Brief Summary
To investigate the safety of thymic humoral factor (THF gamma 2), its effect on HIV load based on at least a 75 percent decrease in HIV quantitative PCR RNA copies/ml, and its persistence when administered in combination with an antiretroviral nucleoside derivative (zidovudine; AZT). To assess the effects of THF gamma 2 on T-cells, quality of life, and progression of disease.
- Detailed Description
All patients receive 12 weeks of AZT before being randomized to self-administer one of two doses of THF gamma 2 or placebo for 15 consecutive days and then twice weekly for an additional 50 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (10)
Chelsea Village Med Ctr
🇺🇸New York, New York, United States
Goodgame Med Group
🇺🇸Maitland, Florida, United States
Infectious Disease Physicians Inc
🇺🇸Annandale, Virginia, United States
UCI
🇺🇸Irvine, California, United States
Southwest Community Based AIDS Treatment Group - COMBAT
🇺🇸Los Angeles, California, United States
Portland Veterans Adm Med Ctr / Rsch & Education Grp
🇺🇸Portland, Oregon, United States
Dr Alfred F Burnside Jr
🇺🇸Columbia, South Carolina, United States
San Francisco Veterans Administration Med Ctr
🇺🇸San Francisco, California, United States
Mem Hosp Hollywood
🇺🇸Hollywood, Florida, United States
Gottlieb Med Group
🇺🇸Sherman Oaks, California, United States